Livetiracetam - Anti-epiletic-(May 2007)
Drug Name:Livetiracetam - Anti-epiletic-(May 2007)
List Of Brands:
Indication Type Description:
Indication
Dosages/ Overdosage Etc
Indication:
LIST OF DRUGS DURING 2007
Sr.No- 73
Name of the Drug- Livetiracetam conc.for infusion
100mg/ml (new dosage form) Pharmacological Classification- As adjunctive therapy in partial onset seizures
in adults with epilepsy when oral administration
is tempoarily not feasible
Date of Approval- 21-05-07
Approved by U.S.FDA on 30-12-2007 (Ref- FDA approved List- 2007)
LIST OF DRUGS DURING 2007
Sr.No- 142
Name of the Drug- Livetiracetam Tablet (addl.indication)
100mg/ml
Pharmacological Classification- i. As monotherapy in partial onset seizures with or
without secondary generalisation in patients with
16 years of age with newly diagnosed epilepsy
ii. As adjunctive therapy in myoclonic seizures in
adults and adolescents from 12 years of age
with juvenile myoclonic epilepsy .
In primary generalised tonic-clonic seizures in
adults and adolescents from 12 years of age
with idiopathic generalised epilepsy
Date of Approval- 09-10-07
Approved by U.S.FDA on 30-12-2007 (Ref- FDA approved List- 2007)
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Livetiracetam Conc. for Infusion 21-05-2007 to
100mg/ml ( New Dosage Form) 23-01-2012
As adjunctive therapy in partial onset seizures in adults with epilepsy
when oral administration is temporarily not feasible as an adjunct to
improve glucemic control in adults with type 2 diabetes mellitus.
Important limitations are-
i.Should not be used in patients with type 1 diabetes or for the treatment
of diabetic ketoacidosis
ii. Has not been studied in combination with insulin.
Dosages/ Overdosage Etc:
As adjunctive therapy in partial onset seizures in adults with epilepsy
when oral administration is temporarily not feasible as an adjunct to
improve glucemic control in adults with type 2 diabetes mellitus.
Important limitations are-
i.Should not be used in patients with type 1 diabetes or for the treatment
of diabetic ketoacidosis
ii. Has not been studied in combination with insulin.
